Patients with prostate cancer from sexual minority groups experience considerably worse quality of life following prostate cancer treatment than heterosexual patients. Improved inclusivity as well as cultural humility training at the physician, institution and system levels are warranted to address inequalities in quality-of-life outcomes.
This is a preview of subscription content
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Rosser, B. R. S. et al. Understanding prostate cancer in gay, bisexual, and other men who have sex with men and transgender women: a review of the literature. Curr. Sex. Health Rep. 11, 430–441 (2019).
Rosser, B. R. S. et al. Health disparities of sexual minority patients following prostate cancer treatment: results from the Restore-2 study. Front. Oncol. 12, 812117 (2022).
Ussher, J. M. et al. Health-related quality of life, psychological distress, and sexual changes following prostate cancer: a comparison of gay and bisexual men with heterosexual men. J. Sex. Med. 13, 425–434 (2016).
Haggart, R. et al. Comorbidity prevalence and impact on quality of life in gay and bisexual men following prostate cancer treatment. Sex. Med. 9, 100439 (2021).
McInnis, M. K. & Pukall, C. F. Sex after prostate cancer in gay and bisexual men: a review of the literature. Sex. Med. Rev. 8, 466–472 (2020).
Polter, E. J. et al. Creation and psychometric validation of the sexual minorities and prostate cancer scale (SMACS) in sexual minority patients-the Restore-2 study. J. Sex. Med. 19, 529–540 (2022).
Lee, T. K. et al. Development of a sexual quality of life questionnaire for men-who-have-sex-with-men with prostate cancer. Sex. Med. 10, 100480 (2022).
Alpert, A. et al. What exactly are we measuring? Evaluating sexual and gender minority cultural humility training for oncology care clinicians. J. Clin. Oncol. 38, 2605–2609 (2020).
Berrahou, I. K., Snow, A., Swanson, M. & Obedin-Maliver, J. Representation of sexual and gender minority people in patient nondiscrimination policies of cancer centers in the United States. J. Natl Compr. Cancer Netw. https://doi.org/10.6004/jnccn.2021.7078 (2022).
A.R. declares stock and other ownership interests: ECOM Medical; consulting or advisory role: Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Immunomedics and Gilead Sciences; speakers’ bureau: Janssen, Astellas Medivation, Pfizer, Novartis, Sanofi, Genentech/Roche, Eisai, AstraZeneca, Bristol Myers Squibb, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/Astellas, Myovant Sciences, Gilead Sciences and AVEO; research funding: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Macrogenics, Astellas Pharma, BeyondSpring Pharmaceuticals, BioClin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics and Epizyme; and travel, accommodations and/or expenses: Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis and AstraZeneca. D.J.B. declares no competing interests.
About this article
Cite this article
Benjamin, D.J., Rezazadeh, A. Quality of life in sexual minorities following prostate cancer treatment. Nat Rev Urol 19, 323–324 (2022). https://doi.org/10.1038/s41585-022-00601-5